Suedzucker AG (0G7B)
London Exchange · UK · prices in EUR · close of 21 Oct 2026
Key indicators
| Last close | EUR 11.66 |
|---|---|
| 52-week range | 8.97 – 13.21 |
| Return, 1 month / 3 months | −3.7% / −0.6% |
| Return, 1 year / 3 years | +20.8% / +9.6% |
| Trend | Above 200-day, below 50-day |
| RSI (14) | 40 |
| Volatility (1 year) | 32.7% |
| Worst drawdown (1 year) | -19.8% |
| Average daily value traded | 0.03M EUR |
| Dividend yield | – |
Market X-Ray price-based
Five-year price chart navy: price · brown: 200-day average
About the company
Suedzucker is a German food and ingredients group based in Mannheim. Its core business is producing sugar from sugar beet, which it supplies to food manufacturers, retailers and industrial customers across Europe. The company also makes speciality ingredients such as functional food additives and starches, and it operates in crop-based energy through ethanol and related products. Its customers include food and beverage producers, the pharmaceutical and animal feed industries, and agricultural partners who supply the beet it processes.
Suedzucker AG trades under the code 0G7B on the London Exchange in UK, with its price quoted in euros (EUR). Our dividend records, which start in 2019, show payments in 7 different calendar years. The Market X-Ray on this page is price-based and compares it with other stocks on the same exchange; it does not measure how healthy the business is.
Summary
Suedzucker AG (0G7B) trades on the London Exchange in UK. It last closed at EUR 11.66 on 21 October 2026.
Its price-based Market X-Ray is 56 out of 100 (a fair price profile), ranking 1,679 of 3,787 stocks on this exchange. The score describes how the stock has traded: trend, momentum, risk, liquidity and dividends, each ranked against the other stocks on its own exchange. It does not measure how healthy or cheap the business is.
Over the last year the price rose 20.8% and over the last three months it fell 0.6%. Returns are price returns, dividends not included.
Fundamental measures (valuation, growth, financial health) are not shown: we do not yet hold financial statements for this market.
The five lenses in numbers each metric is ranked against the other stocks on London Exchange
| Lens and metric | Value | Score | Reading |
|---|---|---|---|
| Trend | 68 · Fair | Mixed trend against its averages. | |
| Above 200-day average | 4.3% | ||
| From 52-week high | -11.7% | ||
| Momentum | 56 · Fair | Typical recent returns for this exchange. | |
| 3-month return | -0.6% | ||
| 6-month return | 0.3% | ||
| 12-month return, skipping the last month | 25.4% | ||
| Stability (higher is calmer) | 64 · Fair | Typical risk for this exchange. | |
| Volatility, 1 year (lower is calmer) | 32.7% | ||
| Worst drawdown, 1 year (smaller is calmer) | -19.8% | ||
| Liquidity | 21 · Weak | Thinly traded: prices can jump and exits can be hard. | |
| Average daily value traded | 0.03M EUR | ||
| Zero-volume days | 5.0% | ||
| Income | – | Pays no dividend. | |
| Dividend yield | – | ||
| Years with dividends | 4 |
Strengths
No lens stands out as a clear strength against its exchange.
Weak spots
- Liquidity: Thinly traded: prices can jump and exits can be hard.
Returns
| 1 week | −4.9% |
|---|---|
| 1 month | −3.7% |
| 3 months | −0.6% |
| 6 months | +0.3% |
| 1 year | +20.8% |
| 3 years | +9.6% |
| 5 years | – |
Signals
| 50-day / 200-day average | 12.36 / 11.18 |
|---|---|
| Golden / death cross (60 days) | None |
| New 52-week high | No |
| Bullish RSI divergence | No |
| Average daily range (ATR) | 0.39 |
Technical summary
Recent dividends
| Ex-dividend date | Amount per share |
|---|---|
| 18 Jul 2025 | EUR 0.2000 |
| 19 Jul 2024 | EUR 0.9000 |
| 14 Jul 2023 | EUR 0.7000 |
| 15 Jul 2022 | EUR 0.4000 |
| 16 Jul 2021 | EUR 0.2000 |
| 17 Jul 2020 | EUR 0.2000 |
How to read this report
Every number comes from end-of-day prices and dividends. The Market X-Ray describes how the stock has traded, ranked against the other stocks on London Exchange; it does not measure how healthy or cheap the business is. The fundamental X-Ray (financial health, valuation, growth) needs financial statements, which we hold today for US stocks. See the methodology page. Educational only, not financial advice.